Use of intravenous iron without erythropoietin for the treatment of anemia of hemodialysis
| Autor: | Leticia Elgueta S, Miriam Alvo A, Alejandro Cotera F, Henry Aragón V |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Iron compunds
medicine.medical_specialty biology business.industry Anemia medicine.medical_treatment Anemia iron-deficiency General Medicine Iron deficiency medicine.disease Gastroenterology Ferrous Surgery Ferritin Erythropoietin Hemodialysis Internal medicine medicine biology.protein business Adverse effect After treatment medicine.drug |
| Zdroj: | Revista médica de Chile, Volume: 130, Issue: 8, Pages: 865-868, Published: AUG 2002 Revista médica de Chile v.130 n.8 2002 SciELO Chile CONICYT Chile instacron:CONICYT |
| ISSN: | 0034-9887 |
| DOI: | 10.4067/s0034-98872002000800004 |
| Popis: | Background: In the last two decades, the use of erythropoietin for the correction of anemia in hemodialysis patients has been recommended. In Chile, only 10% of hemodialysis patients use erythropoietin, therefore, the correction of iron deficiency must be optimized. Aim: To report the effects of intravenous iron without erythropoietin in the management of anemia in hemodialysis patients. Material and methods: Retrospective analysis of 42 patients that received intravenous ferrous sacarate in doses of 100 mg/week during 5 weeks and 100 mg bimonthly during six months. These patients did not receive erythropoietin. Results. Thirty six patients had iron deficiency. Basal ferritin was 137±22 µg/l and increased to 321±28 µg/l after treatment. Packed red cell volume increased from 24±2% to 29±3%. No adverse effects were reported. Conclusions: Iron deficiency is frequent in hemodialyzed patients. Intravenous iron is safe and effective in the treatment of iron deficiency in these patients (Rev Méd Chile 2002; 130: 865-8) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|